ACH
BEAM icon

ArrowMark Colorado Holdings’s Beam Therapeutics BEAM Stock Holding History

ArrowMark Colorado Holdings’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-21,000
Closed -$378K – 304
2020
Q1 		$378K Buy
+21,000
New +$456K 0.01% 282

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

ArrowMark Colorado Holdings's BEAM Position: Q2 2020 in Review

ArrowMark Colorado Holdings sold out of Beam Therapeutics (BEAM) in Q2 2020, closing a stake of 21,000 shares — an estimated $378K sold.

ArrowMark Colorado Holdings first reported a position in BEAM in Q1 2020 and held it in 1 quarter. The position peaked at $378K in Q1 2020. 71 funds tracked by Wall St. Rank hold BEAM as of Q2 2020.

  • ArrowMark Colorado Holdings reported no remaining Beam Therapeutics position as of Q2 2020 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 21,000 Beam Therapeutics shares in Q2 2020, an estimated $378K.
  • ArrowMark Colorado Holdings first reported a position in Beam Therapeutics in Q1 2020 and held it in 1 quarter.
  • ArrowMark Colorado Holdings's Beam Therapeutics position peaked at $378K in Q1 2020.
  • 71 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2020.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2020, filed 14 Aug 2020.